









Markets
/
Stocks
/
nasdaq-clym
/

Climb Bio Inc

CLYM

View Detailed Chart

1.711USD

+0.261+17.97%

Market hours （ET）Quotes delayed by 15 min

115.60MMarket Cap

LossP/E TTM



Climb Bio Inc

1.711

+0.261+17.97%

Overview Company Financials

Financials

Intraday

30m

Today

+17.97%

5 Days

+17.97%

1 Month

+33.64%

6 Months

-14.04%

Year to Date

-4.97%

1 Year

-78.32%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 2 analysts

STRONG BUY

Current Rating

10.000

Target Price

589.66%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Climb Bio Inc

CLYM

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(4)

Neutral(3)

Buy(5)

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.007

Neutral

RSI(14)

53.495

Neutral

STOCH(KDJ)(9,3,3)

32.430

Sell

ATR(14)

0.106

High Vlolatility

CCI(14)

-60.316

Neutral

Williams %R

66.600

Sell

TRIX(12,20)

0.703

Sell

StochRSI(14)

19.211

Oversold

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

1.496

Buy

MA10

1.471

Buy

MA20

1.423

Buy

MA50

1.318

Buy

MA100

1.289

Buy

MA200

1.957

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Climb Bio, Inc., formerly Eliem Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.

Ticker SymbolCLYM

CompanyClimb Bio Inc

CEODr. Aoife M. Brennan

Websitehttps://climbbio.com/